Noteworthy lectures focus on cutting edge therapeutics

Article
Conference|San Antonio Breast Cancer Symposium (SABCS)

Oncology NEWS International guest editor Dr. Andrew D. Seidman recommends SABCS 2008 lectures on modern molecular science, molecular profiling, and the American Association of Cancer Research distinguished lectureship in breast cancer research.

SAN ANTONIO-Oncology NEWS International guest editor Dr. Andrew D. Seidman recommends the following SABCS 2008 lectures:

  • William L. McGuire memorial lecture What is cancer? How modern molecular science is challenging traditional views," given by Larry Norton, MD, Memorial Sloan-Kettering Cancer Center, New York



  • Mini-symposium "Molecular Profiling for guiding therapeutic decisions," moderated by Suzanne A.W. Fuqua, PhD, from Baylor College of Medicine, Houston, and Laura van't Veer, PhD, Netherlands Cancer Institute, Amsterdam. Topics: RNA, personalized medicine, predictors of response to adjuvant therapy.



  • American Association of Cancer Research (AACR) distinguished lectureship in breast cancer research Titled "Deconstructing metastasis," the lecture will be delivered by Joan Massagu, PhD, of Memorial Sloan-Kettering Cancer Center, New York

 

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content
According to the developers, giredestrant is the first oral SERD to display beneficial DFS in early-stage breast cancer in the adjuvant setting.

Giredestrant Exhibits DFS Improvement in Early-Stage Breast Cancer

Roman Fabbricatore
November 18th 2025
Article

According to the developers, giredestrant is the first oral SERD to display beneficial DFS in early-stage breast cancer in the adjuvant setting.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from the ASCENT-07 trial show an early trend toward improved overall survival with sacituzumab govitecan vs chemotherapy.

Sacituzumab Govitecan Misses PFS End Point in Metastatic Breast Cancer

Russ Conroy
November 11th 2025
Article

Data from the ASCENT-07 trial show an early trend toward improved overall survival with sacituzumab govitecan vs chemotherapy.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable with prior reports of each individual agent.

Palazestrant Combo Shows Preliminary Activity in ER+/HER2– Breast Cancer

Russ Conroy
November 6th 2025
Article

The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable to prior reports of each individual agent.

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

Ariana Pelosci
November 5th 2025
Article

Aditya Bardia, MD, highlights the successes and challenges associated with ADC treatments in breast cancer.